SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Real Asian Hours

$CHINAWINS is trending amid community excitement, with many noting the strong branding and momentum. The crypto is seeing increased attention from Phantom Wallet users, who are actively 'stacking bags.' However, some users are expressing skepticism, labeling it a potential scam or pump-and-dump.

Zoracles

Zoracles ($ZORA) is trending as community members discuss its potential listing on additional exchanges and speculate on future price movements. Bullish sentiment is fueled by its association with a social media platform where every post can be tokenized, attracting attention in the crypto space. Some traders are closely watching for entry points, with many believing $ZORA has strong long-term potential.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

PGY is trending amidst discussions about its volatility, potential for growth, and recent market behavior, with community members weighing bullish and bearish perspectives. Analysts' price target adjustments and debates around earnings outlook are fueling the conversation. Some investors are expressing concerns about potential portfolio losses, while others remain optimistic about the company's long-term prospects and AI-driven approach.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion ($ACON) is trending due to community speculation about a potential short squeeze and significant gains, possibly as early as Monday. The stock's low float is a key talking point, with some investors hoping for a rapid price increase, while others cite concerns about the company's history of reverse splits and potential dilution.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions about a recent market dip and potential impacts from trade tensions involving China. Community members are debating whether this is a buying opportunity or the start of a larger correction, with some highlighting potential manipulation and others emphasizing Bitcoin's long-term value proposition. Concerns about leveraged positions and potential liquidations are also circulating.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

Ondo is trending as the community discusses its potential in the Real World Asset (RWA) tokenization space and possible connections to traditional finance giants. Conversations revolve around its long-term prospects and utility, with some anticipating significant growth. Recent news and partnerships may be acting as catalysts, though opinions are divided on its immediate price action.

UWM Holdings Corp. is a wholesale mortgage lender, which underwrites and provides closing documentation for residential mortgage loans originated by independent mortgage brokers, correspondents, small banks and local credit unions. The firm provides independent mortgage advisors with a set of technologically driven tools and a value proposition that enables them to offer borrowers that meet the credit rating standards compelling financing alternatives. The company was founded in 1986 and is headquartered in Pontiac, MI.

UWM Holdings Corporation - Ordinary Shares - Class A

UWMC is trending as investors discuss its upcoming earnings and potential benefits from falling rates, particularly in relation to derivative assets and Q3 performance. The community is weighing the impact of market dynamics and interest rate trends on the company's future profitability. Some are also closely monitoring the progress of a settlement related to past claims.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending as the community discusses its connection to Donald Trump Jr. and the company's potential role in upcoming drone contracts. Conversations also highlight the broader drone sector and Unusual Machine's position as a component supplier, with some anticipating significant growth and others expressing concerns about dilution and revenue.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as community members discuss the potential impacts of China's export restrictions on lithium batteries and materials, with some anticipating increased government support and partnerships for domestic suppliers. Chatter revolves around the upcoming PFS report and potential funding, while some express concerns about possible pullbacks and the influence of market makers. Overall, the sentiment appears bullish, with many highlighting ABAT's potential role in securing America's metal supply chain.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM) is trending as traders discuss its potential, particularly around AI narratives and anticipation for a possible Binance listing. The community is closely watching for a breakout, speculating on potential price targets and highlighting whale activity. Some traders express frustration with price fluctuations, while others remain optimistic about long-term gains and potential news.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR

With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m...

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy 

Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.

Gilead Sciences (GILD) announced on Monday that it has entered into settlement agreements with multiple players to resolve patent litigations.The company stated in a filing that it settled with generic manufacturers Lupin, Cipla, and Laurus Labs, who filed abbreviated new drug applications with the U.S. Food and Drug Administration (FDA) to market generic versions of Biktarvy.Shares of the company rose marginally at the time of writing. On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/GILD">GILD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.&nbsp; Under the settlements <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000882095/000088209525000041/gild-20251006.htm">entered</a>, no generic entry is expected for Biktarvy before April 1, 2036, in the United States, Gilead said. Biktarvy was Gilead’s best-selling drug in 2024. Biktarvy sales increased 13% year-over-year to $13.4 billion for the full year 2024. The HIV drug, in fact, accounted for 47% of the company’s overall product sales in the 12 months through the end of December.Biktarvy tablets contain Bictegravir (50 mg), Emtricitabine (200 mg), and Tenofovir Alafenamide (25 mg). Wells Fargo noted that the settlement would extend the U.S. patent to April 2036 from the current December 2033. The firm believes that the Biktarvy patent expansion gives Gilead a longer runway and places it in the same bracket as AbbVie (ABBV). The firm has assigned an ‘Overweight’ rating to Gilead, with a price target of $140 per share.The price target of $140 implies a potential upside of over 24% from the stock’s closing price on Friday. GILD stock is up by 22% this year and by 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amgen-to-sell-cholestrol-drug-for-approximately-60-percent-discount/ch6R3MmR3gi">Amgen To Sell Cholesterol Drug For Approximately 60% Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway

The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.

Equity

The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.


Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) reached $112.69 at the closing of the latest trading day, reflecting a +1.93% change compared to its last close.

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline 

Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

Gilead Sciences (GILD) concluded the recent trading session at $110.99, signifying a -2.36% move from its prior day's close.

Lupin shares climbed on Thursday after the U.S. Food and Drug Administration gave a tentative approval to the company to sell a generic version of an HIV treatment.The approval is for a 50 mg/200 mg/25 mg tablet that matches Biktarvy, Gilead Sciences’ blockbuster drug widely used in HIV care.&nbsp;Lupin said the tablets will be manufactured at its Nagpur facility and will be available for adults and pediatric patients weighing at least 25 kgs.Analyst ViewWhile the approval is tentative and pending patent and exclusivity clearance, SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Japfinserve">Varunkumar Patel</a> said it places Lupin in a strong position to capture a high-value, stable demand market once launch is viable.<stembedurl>https://stocktwits.com/Japfinserve/message/629928277</stembedurl>Patel highlighted that HIV medicines enjoy consistent demand and are less cyclical compared with other therapies. Patel said a successful entry could boost Lupin’s U.S. revenues and margins, while also strengthening its complex generics pipeline.&nbsp;He also said that the approval of the Nagpur plant reflects the regulator's confidence in Lupin's manufacturing compliance.Patel said that challenges remain, such as patent suits, pricing pressure and timing of the launch.&nbsp;He said the news enhances investor sentiment toward Lupin’s U.S. portfolio. While the immediate earnings contribution may be limited, Patel noted it strengthens the medium-term growth visibility of the company.Technical OutlookPatel said Lupin is trading near ₹2,005. He identified support in the ₹1,975–₹1,985 zone and resistance at ₹2,055–₹2,060. The Relative Strength Index (RSI) is hovering near 54, showing neutral momentum.He added that a decisive breakout above ₹2,060 on strong volumes could open further upside, while a fall below ₹1,975 may lead to downside pressure.What Is The Retail Mood?On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/LUPIN.NSE">Lupin’s stock</a> has declined 15.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lupin Gains On FDA Nod For HIV Drug; Technicals Suggest Potential Upside Above ₹2,060

The tablets will be manufactured at Lupin’s Nagpur facility and are indicated for adults and pediatric patients weighing at least 25 kg.

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$117.18
Prev Close	$116.74
Open	$117.65
Dividend Yield	3.33%
50-Day Moving Average	$114.65
Beta	0.40
Avg. Volume	7.21M
PE Ratio	23.31

52-Week High	$121.83
52-Week Low	$84.34
Market Capitalization	$145.4B
EPS (Annual)	$0.3825
Price to Book	7.40
Revenue Per Employee	$1.63M
Enterprise Value/EBITDA	N/A

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILDGilead Sciences, Inc.